Kubota Pharmaceutical Holdings: (Correction) Partial correction of 'Japan Retinal Pigmentary Dystrophy Association submits request to PMDA for early approval of 'Emiclustat hydrochloride' a candidate for Stargardt disease treatment'.

JPX · Jun 6 13:00

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

窪田製薬ホールディングス：（訂正）「日本網膜色素変性症協会がＰＭＤＡに要望書を提出 スターガルト病治療薬候補『エミクススタト塩酸塩』の早期承認を求める」の一部訂正について

Kubota Pharmaceutical Holdings: (Correction) Partial correction of 'Japan Retinal Pigmentary Dystrophy Association submits request to PMDA for early approval of 'Emiclustat hydrochloride' a candidate for Stargardt disease treatment'.

Risk Disclaimer

Statement

窪田製薬ホールディングス：（訂正）「日本網膜色素変性症協会がＰＭＤＡに要望書を提出スターガルト病治療薬候補『エミクススタト塩酸塩』の早期承認を求める」の一部訂正について